Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLong-Term Debt IssuancesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Haemonetics (HAE) Accumulated Depreciation & Amortization (2017 - 2025)

Haemonetics has reported Accumulated Depreciation & Amortization over the past 16 years, most recently at $539.6 million for Q4 2025.

  • For Q4 2025, Accumulated Depreciation & Amortization fell 38.35% year-over-year to $539.6 million; the TTM value through Dec 2025 reached $539.6 million, down 38.35%, while the annual FY2025 figure was $553.1 million, 14.61% down from the prior year.
  • Accumulated Depreciation & Amortization for Q4 2025 was $539.6 million at Haemonetics, up from $522.8 million in the prior quarter.
  • Over five years, Accumulated Depreciation & Amortization peaked at $875.3 million in Q4 2024 and troughed at $508.2 million in Q2 2025.
  • A 5-year average of $622.6 million and a median of $635.8 million in 2023 define the central range for Accumulated Depreciation & Amortization.
  • Biggest five-year swings in Accumulated Depreciation & Amortization: skyrocketed 32.49% in 2024 and later tumbled 38.35% in 2025.
  • Year by year, Accumulated Depreciation & Amortization stood at $599.7 million in 2021, then increased by 1.83% to $610.7 million in 2022, then grew by 8.18% to $660.6 million in 2023, then surged by 32.49% to $875.3 million in 2024, then tumbled by 38.35% to $539.6 million in 2025.
  • Business Quant data shows Accumulated Depreciation & Amortization for HAE at $539.6 million in Q4 2025, $522.8 million in Q3 2025, and $508.2 million in Q2 2025.